ArcticZymes Technologies Reports Strong Q4 and FY 2025 Results: Accelerating Sales Growth and Improved Profitability
Tromsø, Norway, February 12, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet.
ArcticZymes Technologies ASA – Invitation to Capital Markets Day 2026 - 6 March 2026, 09:00–12:00 CET - Stockholm, Sweden
ArcticZymes Technologies ASA invites investors, analysts and other stakeholders to its Capital Markets Day on 6 March 2026, 09:00–12:00 CET (registration and coffee from 08:30).
Invitation to presentation of Q4 and FY 2025 results
The Company will host a virtual Q4 and 12M 2025 presentation for investors, analysts and media at 10:00 CET on Thursday, 12 February, 2026.
ArcticZymes Technologies Reports Q3 2025 Results: Continued Growth Momentum and Strengthened Profitability
Tromsø, Norway, November 6, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the third quarter of 2025, reporting strong topline growth and solid operational performance.
ArcticZymes ASA Appoints New Exclusive European Distributor for its Bioprocess Nuclease Range
ArcticZymes is pleased to announce a new, exclusive European distributor agreement with Brenntag Specialists Pharma to compliment its existing commercial team, supply the SAN-HQ and M-SAN HQ product lines.